

Tuesday, 26 October 2021			
Conference Portal Opens: Create your User Profile & Get Oriented & Join the Virtual Exhibition			
12:30	Welcome & Introductions	Falk Klar, PDA Europe	
12:35	LIVE: Welcome from the Chairs	Mai Huynh, <i>U.S. FDA</i> Martin Müllner, <i>Boehringer Ingelheim</i>	
12:40	Keynote: Companion vs Cattle Animals – How Veterinary Manufacturing is Impacted	Luc Pisarik, Boehringer Ingelheim	
Updates in the		Moderators: Martin Müllner, <i>Boehringer Ingelheim</i> Mindy Hoskins, <i>WEST</i>	
13:00	LIVE Session Introduction The regulatory landscape in the Animal Health sector is complex and dependent on both the product type and geographic market. Globally there are numerous regulatory authorities with various levels of harmonization impacting Animal Health. In this session the differences between USDA and U.S. FDA regulation are outlined. One Health inextricably connects animal, human and environmental health. We will learn about the U.S. FDA perspective on this One Health Initiative. Furthermore, we will receive information about the upcoming EMA Veterinary Medicines Regulation (EU) 2019/6, which will become applicable on 28th January 2022.		
13:05	Jurisdiction between USDA and U.S. FDA	Kate Huebner <i>, U.S. FDA</i> Matt Erdman <i>, USDA</i>	
13:15	The One Health Initiative in the US	Marianne P. Martinson, U.S. FDA	
13:35	Regulation (EC) 2019/6: the Driving Force for Change in European VMP Registration	Klaus Hellmann, <i>Klifovet AG</i>	
13:55	LIVE Q&A, Discussion		
14:30	Break & Virtual Exhibition		



Module II

Tuesda	ay, 26 October 2021	
		Moderators
Drug and	Supply Shortages in the Animal Health Industry	Mai Huynh <i>, U.S. FDA</i>
		Mike Schäfers, Aenova Group
15:00	LIVE Session Introduction The pandemic has resulted in several shortages of conthe other. As supply chain becomes more and more configuration in the ingredients and/or non ingredients supplies (e.g. vially bags, tubing, etc.) have forced all of us to react and continuous in human has been a highlight throughout the panded exception. This session will present examples of animodiscuss opportunities where regulatory priorities may veterinary products. Case studies where Quality Risk manufacturers mitigate the effects of supply shortage long term planning will also be presented. Animal Drug Shortage Coordinator and Quality Assessioning the live Q&A session to provide additional institutions.	complex due to globalization, shortages of ls, stoppers, sterilizing filters, single use adapt differently. Shortage of drugs for use emic; veterinary medicinal drugs are not an all drug shortages in the United States and by be shifted for medically necessary. Management and its tool can help use and strengthen operation resiliency for assor from the United States will also be
15:05	U.S. Veterinary Drug Shortages: Industry Views on Potential Changes to Regulatory Policy	Jeanne Greenwald, <i>Intervet</i>
15:20	PDA Task Force on Quality Risk Management: Manag Supply Shortages	Tiffany Baker, <i>ValSource</i>
15:40	LIVE Q&A, Panel Discussion	Jeanne Greenwald, <i>Intervet</i> Tiffany Baker, <i>ValSource</i> Arnel B. Peralta, <i>U.S. FDA</i> Renée Blosser, <i>U.S. FDA</i> Mai Huynh, <i>U.S. FDA</i> Mike Schäfers, <i>Aenova Group</i>
16:15	Break & Virtual Exhibition	



Module III

Wednesday, 27 October 2021			
	Experience: Working Groups ation of the Annex 1 Revision in the Animal Healt	th Industry	Moderators Martin Folger, <i>Boehringer Ingelheim</i> Olivier Chancel, <i>Boehringer Ingelheim</i>
16:45	LIVE Session Introduction The revision of the EU GMP Annex 1 will be pure are applicable not only to the Human Health of this session, we will have the chance to listen new Annex 1: Contamination Control and Bar workshop groups in separate live video chat refaced in the Animal Health sector specifically.	Industry but to two case rier Systems cooms will of	also to the Veterinary Industry. Within studies on hot topics discussed in the Following the presentations 2 fer a deep dive into the challenges
16:50	Topic 1 - Contamination Control Contamination Control Through Efficient Clea Disinfection - A Case Study	aning and	Subrata Chakraborty, GxPFONT Consulting Group
17:10	Topic 2 – Barrier Systems Differences in the Contamination Control Stra Barrier Systems - A Case Study	ategy using	Richard Denk <i>, SKAN</i>
17:30	LIVE Q&A, Discussion		
17:45	 Group 1 Contamination Control What differences are apparent between Human and Animal Industry and how does this impact the implementation of the new guidelines? How can companies be compliant and what strategy along the whole supply chain will be feasible? How does QRM relate to the proposed, revised Annex 1 CCS? 	 What is Health the proset-up? Is the time to the time the time that set is the time that set is	rrier Systems the typical set-up currently in Animal Manufacturing Facilities and how can posed requirements be met in each rend towards closed or open RABS? pecifications does equipment need to pecifically in the veterinary industry?
18:20	LIVE: Summary of Working Groups by Modera	ator groups	



18:30	End of Conference Day 1 and Live Poster Lounge
18:30 – 19:30 C	EST Networking Event – Poster Lounge

Module IV:

Wednesday, 27 October 2021			
12:00 CEST: Conference Portal Opens: Create your User Profile & Get Oriented & Join the Virtual Exhibition			
113:00	Development. Lesting and Aseptic Processing of	Moderators: Alexander Trautmann, A&O Pharma Luc Pisarik, Boehringer Ingelheim	
LIVE Session Introduction			
11 3.02	Overview of the Fundamental Principles Governing Aseptic Processing	Tony Dinis, <i>CEVA</i>	
13:25	Monocyte Activation Test: A Comprehensive Approach to Assessing Pyrogenic and/or Non-pyrogenic Contaminants in Biologics and Medical Device		
11 3.42	Case Study: Flexible Fill/Finish Line for Multiple Veterinary Products at High Outputs	Laura Moody, Syntegon Pharma Technology	
14:05	LIVE Q&A, Discussion		
14:30	Break & Virtual Exhibition		



Module V

Wednesday, 27 October 2021		
15:00	Novel Approaches in the Animal Health Industry	Moderators Marit Lemke, <i>Elanco</i> Hanjo Hennemann, <i>VeroVaccines</i>
LIVE Session Introduction This module provides insight into new approaches for R&D in the animal health industry. It spans across early research (antimicrobial drug resistance), platforms (recombinant antibody discovery), analytical development (shortening development timelines using simulations) to late phase development activities (decision on sustainable packaging).		
15:05	An Approach to Sustainable Packaging in the Animal Health Space	Elke Wagner, Elanco Animal Health Uwe Müller, Elanco Animal Health
15:25	Case Study – Computational Simulation Support for Injection Device Development	Max Rehpenning, <i>Elanco Animal Health</i> Jeremy Hemmingway, <i>Stress</i> <i>Engineering Services</i>
15:45	Species-Specific Therapeutic Antibodies as New Treatment Options in Veterinary Medicine	Markus Waldhuber, <i>Adivo</i>
16:05	Exploring Microbial Virulence Factors: Roles as Potential Therapeutic Targets and Relationships to Antimicrobial Drug Resistance	Heather Harbottle, U.S. FDA
16:25	LIVE Q&A, Discussion	
17:00	LIVE Conference Closing & Summary	Mai Huynh, <i>U.S. FDA</i> Martin Müllner, <i>Boehringer Ingelheim</i>
17:15	Thank You Remarks and Farewell	Falk Klar, PDA Europe

Agenda is subject to change without notice